bonusdeuceswildpoker| Shi Siyao Group (02005.HK): Has obtained the drug production registration approval from the Food and Drug Administration for Linezolid dry suspension (5ml: 100mg)
Gelonghui announced on April 23 that Shi Siyao Group (02005.HK) had obtained a report from the State Food and Drug Administration of China on linezolid dry suspension (5ml)bonusdeuceswildpoker:100mg)bonusdeuceswildpokerThe drug production registration approval letter belongs to Class 4 of chemical drugs and is deemed to have passed the consistency evaluation.
Linezolid dry suspension is an oral suspension type. The Group is the first domestic company to be approved. It has previously obtained production approvals for linezolid's raw materials and injections. Linezolid dry suspension can be used in newborns, children and adult patients, mainly for the treatment of nosocomial pneumonia caused by sensitive strains of specific microorganisms, community-acquired pneumonia, skin and skin soft tissue infections, and vancomycin-resistant Enterococcus faecium infections
